Finally, another recent study provided evidence that Rucaparib significantly improved PFS in patients with platinum-sensitive ovarian cancer who had achieved a response to platinum-based chemotherapy, thus indicating that PARP inhibitors could be used in the maintenance treatment of HGS-OvCa [47]. Here, PARP1 is linked to ovarian carcinoma.